- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07587710
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function
A Study Investigating the Pharmacokinetic Properties, Safety and Tolerability of NNC0487-0111 in Participants With Various Degrees of Hepatic Impairment and Participants With Normal Hepatic Function
The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people with normal liver function.
Studieoversikt
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Novo Nordisk
- Telefonnummer: (+1) 866-867-7178
- E-post: clinicaltrials@novonordisk.com
Studiesteder
-
-
-
Bratislava, Slovakia, 83101
- Rekruttering
- Summit Clinical Research s.r.o.
-
Malacky, Slovakia, 901 22
- Rekruttering
- Summit Clinical Research s.r.o.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or female (sex at birth).
- Age 18-80 years (both inclusive) at the time of signing informed consent.
- Participants with stable hepatic impairment classified as Child-Pugh grade A, B or C as assessed by the investigator. Stable hepatic impairment is defined as no clinically significant change in disease status, as judged by the investigator.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Severe hepatic impairment
Participants will receive single dose of NNC0487-0111 subcutaneously. |
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors in a skinfold in the thigh. |
|
Eksperimentell: Moderate hepatic impairment
Participants will receive single dose of NNC0487-0111 subcutaneously. |
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors in a skinfold in the thigh. |
|
Eksperimentell: Mild hepatic impairment
Participants will receive single dose of NNC0487-0111 subcutaneously. |
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors in a skinfold in the thigh. |
|
Eksperimentell: Normal hepatic impairment
Participants will receive single dose of NNC0487-0111 subcutaneously. |
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors in a skinfold in the thigh. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
AUC0-∞: The area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose
Tidsramme: From pre-dose on Day 1 up to Day 28
|
Measured as hours*nanomole per liter (nmol*h/L) |
From pre-dose on Day 1 up to Day 28
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cmax: Maximum observed plasma NNC0487-0111 concentration after a single dose
Tidsramme: From pre-dose on Day 1 until Day 5
|
Measured as nanomoles per liter (nmol/L) |
From pre-dose on Day 1 until Day 5
|
|
tmax: Time to maximum observed plasma NNC0487-0111 concentration after a single dose
Tidsramme: From pre-dose on Day 1 until Day 5
|
Measured as hour |
From pre-dose on Day 1 until Day 5
|
|
t½,: Terminal half-life for NNC0487-0111 after a single dose
Tidsramme: From pre-dose on Day 1 up to Day 28
|
Measured as hour |
From pre-dose on Day 1 up to Day 28
|
|
Vz/F: Apparent volume of distribution of NNC0487-0111 after a single dose
Tidsramme: From pre-dose on Day 1 up to Day 28
|
Liter |
From pre-dose on Day 1 up to Day 28
|
|
CL/F: Apparent clearance of NNC0487-0111 after a single dose
Tidsramme: From pre-dose on Day 1 up to Day 28
|
Measured as liter per hour (L/h) |
From pre-dose on Day 1 up to Day 28
|
|
Number of treatment emergent adverse events (TEAEs)
Tidsramme: From pre-dose on Day 1 up to Day 28
|
Measured as number of events |
From pre-dose on Day 1 up to Day 28
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NN9490-8156
- U1111-1320-4875 (Annen identifikator: World Health Organization (WHO))
- 2025-521647-20 (Annen identifikator: European Medical Agency (EMA))
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .